Clinical Trial News and Research

RSS

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C).

29 Jun 2015

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.

29 Jun 2015

Two physician-scientists in search for better Alzheimer's disease treatment

Two of the nation's leading physician-scientists in the search to better understand and treat Alzheimer's disease - William Mobley, MD, PhD, and Michael Rafii, MD, PhD - have been named interim co-directors of the Alzheimer's Disease Cooperative Study (ADCS), a major initiative formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego.

27 Jun 2015

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.

27 Jun 2015

IDC Marketscape recognizes TCS as Leader in Worldwide Life Sciences R&D Risk-Based Monitoring

Tata Consultancy Services, a leading global IT services, consulting and business solutions organization, announced that it has been designated as a Leader in Worldwide Life Sciences R&D Risk-Based Monitoring by global market intelligence firm, IDC, in the "IDC MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor Assessment," (doc #HI255628, April 2015) report.

27 Jun 2015

ASTRO appreciates Supreme Court's decision to uphold consumer tax credits under the ACA

The American Society for Radiation Oncology appreciates yesterday's ruling by the United States Supreme Court affirming the Affordable Care Act in its decision on King v. Burwell.

27 Jun 2015

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma.

27 Jun 2015

Study: High blood pressure linked to lower risk for Alzheimer's disease

A new study suggests that people with a genetic predisposition to high blood pressure have a lower risk for Alzheimer's disease.

27 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

Innovative gene transfer-based treatment for kids with giant axonal neuropathy

University of North Carolina School of Medicine researchers have developed an innovative, experimental gene transfer-based treatment for children with giant axonal neuropathy (GAN).

26 Jun 2015

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry.

26 Jun 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

Weight loss, combined with vitamin D supplements, reduces chronic inflammation

For the first time, researchers at Fred Hutchinson Cancer Research Center have found that weight loss, in combination with vitamin D supplementation, has a greater effect on reducing chronic inflammation than weight loss alone. Chronic inflammation is known to contribute to the development and progression of several diseases, including some cancers.

26 Jun 2015

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection.

25 Jun 2015

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.

25 Jun 2015

Cognitive behavioural therapy can change brain function of people with Tourette syndrome

In addition to its effect on chronic tics, cognitive behavioural therapy (CBT) can change the brain function of people with Tourette syndrome.

25 Jun 2015

Weight loss along with vitamin D supplementation reduces chronic inflammation

25 Jun 2015

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration.

25 Jun 2015

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers have successfully used bone marrow-derived mesenchymal stromal cells (MSCs) to treat a variety of diseases and conditions. Now, using injections of MSCs, a research team in Brazil has successfully treated laboratory rats modeled with severe burns.

25 Jun 2015

WHO prequalifies new male circumcision device to prevent HIV

The ShangRing, a novel medical device for voluntary medical male circumcision, has received prequalification from the World Health Organization (WHO) for use.

25 Jun 2015

Clinical Trial News and Research

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Two physician-scientists in search for better Alzheimer's disease treatment

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

IDC Marketscape recognizes TCS as Leader in Worldwide Life Sciences R&D Risk-Based Monitoring

ASTRO appreciates Supreme Court's decision to uphold consumer tax credits under the ACA

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Study: High blood pressure linked to lower risk for Alzheimer's disease

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Innovative gene transfer-based treatment for kids with giant axonal neuropathy

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Weight loss, combined with vitamin D supplements, reduces chronic inflammation

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Cognitive behavioural therapy can change brain function of people with Tourette syndrome

Weight loss along with vitamin D supplementation reduces chronic inflammation

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

WHO prequalifies new male circumcision device to prevent HIV

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery